Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Consultants in Neurology, Ltd.
292
mi
from 43215
Northbrook, IL
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Consultants in Neurology, Ltd.
292
mi
from 43215
Northbrook, IL
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Associates in Neurology
154
mi
from 43215
Lexington, KY
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Associates in Neurology
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Minneapolis Clinic of Neurology
629
mi
from 43215
Golden Valley, MN
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Minneapolis Clinic of Neurology
629
mi
from 43215
Golden Valley, MN
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Washington University
398
mi
from 43215
Saint Louis, MO
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Washington University
398
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Lou Ruvo Center for Brain Health
1757
mi
from 43215
Las Vegas, NV
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Lou Ruvo Center for Brain Health
1757
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Neuro Medical Care Associates
396
mi
from 43215
Johnson City, NY
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Neuro Medical Care Associates
396
mi
from 43215
Johnson City, NY
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
The Neurological Institute
348
mi
from 43215
Charlotte, NC
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
The Neurological Institute
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Raleigh Neurology Associates
371
mi
from 43215
Raleigh, NC
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Raleigh Neurology Associates
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Hope Neurology MS Center
289
mi
from 43215
Knoxville, TN
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Hope Neurology MS Center
289
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Bhupesh Dihenia, M.D., P.A.
1128
mi
from 43215
Lubbock, TX
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Bhupesh Dihenia, M.D., P.A.
1128
mi
from 43215
Lubbock, TX
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
EvergreenHealth
2001
mi
from 43215
Kirkland, WA
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
EvergreenHealth
2001
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
The Polyclinic
2006
mi
from 43215
Seattle, WA
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
The Polyclinic
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Gomel Regional Clinical Hospital
4933
mi
from 43215
Gomel,
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Gomel Regional Clinical Hospital
4933
mi
from 43215
Gomel,
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
MDH Research LLC
12
mi
from 43215
Westerville, OH
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
MDH Research LLC
12
mi
from 43215
Westerville, OH
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
Central Texas Neurology Consultants, P.A.
1052
mi
from 43215
Round Rock, TX
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
Central Texas Neurology Consultants, P.A.
1052
mi
from 43215
Round Rock, TX
Click here to add this to my saved trials
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center
1661
mi
from 43215
Phoenix, AZ
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center
1661
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1655
mi
from 43215
Phoenix, AZ
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1655
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1052
mi
from 43215
Round Rock, TX
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1052
mi
from 43215
Round Rock, TX
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1138
mi
from 43215
San Antonio, TX
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1160
mi
from 43215
Fort Collins, CO
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1160
mi
from 43215
Fort Collins, CO
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
280
mi
from 43215
Knoxville, TN
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
280
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
157
mi
from 43215
Lexington, KY
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
157
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1
mi
from 43215
Columbus, OH
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1964
mi
from 43215
Pasadena, CA
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1964
mi
from 43215
Pasadena, CA
Click here to add this to my saved trials
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Investigational Trial Site
1154
mi
from 43215
Aurora, CO
Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis
A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Investigational Trial Site
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Long-Term Effects of Torso-Weighting
Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study
Status: Enrolling
Updated:  12/31/1969
Samuel Merritt University, Motion Analysis Research Center
2098
mi
from 43215
Oakland, CA
Long-Term Effects of Torso-Weighting
Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study
Status: Enrolling
Updated: 12/31/1969
Samuel Merritt University, Motion Analysis Research Center
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
479
mi
from 43215
New York, NY
Click here to add this to my saved trials
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.
Status: Enrolling
Updated:  12/31/1969
Evergreen Healthcare
2000
mi
from 43215
Kirkland, WA
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.
Status: Enrolling
Updated: 12/31/1969
Evergreen Healthcare
2000
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
Pilot Diet Study for Multiple Sclerosis
Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS)
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from 43215
New York, NY
Pilot Diet Study for Multiple Sclerosis
Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS)
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from 43215
New York, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Barrow Neurology Clinics
1662
mi
from 43215
Phoenix, AZ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Barrow Neurology Clinics
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Sutter East Bay Medical Foundation
2095
mi
from 43215
Berkeley, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Sutter East Bay Medical Foundation
2095
mi
from 43215
Berkeley, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Southern California- Keck School of Medicine
1970
mi
from 43215
Los Angeles, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Southern California- Keck School of Medicine
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
MS Center of California
1967
mi
from 43215
Newport Beach, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
MS Center of California
1967
mi
from 43215
Newport Beach, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
UC Davis Health System
2042
mi
from 43215
Sacramento, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
UC Davis Health System
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
UCSF Multiple Sclerosis Center
1982
mi
from 43215
San Francisco, CA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
UCSF Multiple Sclerosis Center
1982
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
1154
mi
from 43215
Aurora, CO
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital
540
mi
from 43215
North Haven, CT
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital
540
mi
from 43215
North Haven, CT
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
992
mi
from 43215
Miami, FL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
274
mi
from 43215
Chicago, IL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)
270
mi
from 43215
Chicago, IL
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medicine Neurology & Neurosurgery
345
mi
from 43215
Baltimore, MD
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine Neurology & Neurosurgery
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Harvard Medical School/Brigham & Women's Hospital
643
mi
from 43215
Boston, MA
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Harvard Medical School/Brigham & Women's Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Wayne State University
165
mi
from 43215
Detroit, MI
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Wayne State University
165
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Holy Name Hospital
477
mi
from 43215
Teaneck, NJ
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Holy Name Hospital
477
mi
from 43215
Teaneck, NJ
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
The University of New Mexico - Multiple Sclerosis Specialty Clinic
1331
mi
from 43215
Albuquerque, NM
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
The University of New Mexico - Multiple Sclerosis Specialty Clinic
1331
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
SUNY Buffalo - University Neurology, Inc
303
mi
from 43215
Buffalo, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
SUNY Buffalo - University Neurology, Inc
303
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials